Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles ImmuCell Corporation’s (Nasdaq: ICCC) SEC filings, giving investors structured access to the company’s regulatory disclosures as an animal health business focused on dairy and beef cattle. ImmuCell’s filings include current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, along with other exhibits and agreements.
Through these documents, readers can review ImmuCell’s reported product sales for its First Defense® line, commentary on trends in domestic and international sales, and management’s discussion of gross margins, net income or loss, and backlog dynamics. Filings also describe the development status of Re-Tain®, including the New Animal Drug Application process, investigational product use, and the company’s decision to pause further direct investment after receiving an FDA Incomplete Letter related to a contract manufacturer.
ImmuCell’s SEC reports provide detail on financing arrangements, such as loan agreements and lines of credit with Maine Community Bank, refinancing transactions, and related security interests in company assets. They also disclose corporate governance and leadership changes, including CEO succession, board expansion, and executive employment agreements, as well as other material definitive agreements.
On Stock Titan, these filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain lengthy 10-K and 10-Q reports, highlight key risk factors and business updates, and clarify the implications of Form 8-K events. Users can also quickly identify information about executive and board changes, financing obligations and other material developments affecting ImmuCell’s cattle health-focused operations.
IMMUCELL CORP /DE/ filed an initial Form 3 reporting that Kathy V. Turner is a director of the company. The filing does not list any equity holdings or report any transactions in the company’s securities, serving mainly as a baseline disclosure of insider status.
ImmuCell Corporation reported 2025 product sales of $27.6 million, up 4.3% from 2024, driven mainly by higher Tri‑Shield® demand after clearing prior production backlogs. Gross margin improved from 30% to 41% of product sales as manufacturing efficiency and capacity increased to 4.6 million manufactured units.
The company pivoted strategically in December 2025 to focus on its First Defense® calf‑health franchise and paused further investment in manufacturing Re‑Tain®, recording a $2.7 million non‑cash impairment on related assets. Despite this charge, net loss narrowed to $1.0 million from $2.2 million in 2024, and net operating income turned positive at $1.6 million.
ImmuCell ended 2025 with $3.8 million in cash, net working capital of $13.0 million, and bank debt of $9.1 million at a blended fixed rate of 4.31%. The firm relies heavily on First Defense®, which represented 99% of product sales, and serves a growing biological scours‑prevention market where it estimates about 55% of U.S. calves are still not protected.
ImmuCell director Michael F. Brigham reported a routine stock option exercise. He exercised options for 25,000 shares of Common Stock at $5.84 per share, using previously owned shares to pay the exercise price. In connection with this, 24,052 shares were surrendered to the company to satisfy the option exercise price or related obligations. After these transactions, he directly holds 205,700 shares of ImmuCell Common Stock.
ImmuCell Corp filed an amended insider report showing that President and CEO Paul Francis Olivier te Boekhorst received a grant of 109,500 stock options on January 27, 2026 at an exercise price of $6.265 per share. This amendment corrects the previously reported number of options.
The options were granted in connection with his role as President and CEO. All of the options vest only if ImmuCell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year, making this a fully performance-based award.
ImmuCell Corporation announced a planned Board transition. Longtime director Steven A. Rosgen tendered his resignation effective April 1, 2026, after previously indicating he would not stand for re‑election. To fill the vacancy, the Board elected Kathy V. Turner, also effective April 1, 2026.
Ms. Turner brings more than three decades of commercial leadership in global healthcare and animal health, including senior roles at IDEXX Laboratories and nearly 30 years at Abbott Laboratories. She previously served on Elanco Animal Health’s Board and currently serves on the Board of Veterinarians Without Borders.
Upon joining, she will chair ImmuCell’s Compensation and Stock Option Committee and serve on the Audit Committee. ImmuCell highlighted her experience supporting growth of its First Defense® product line and thanked Mr. Rosgen for eight years of service.
ImmuCell Corporation reported unaudited 2025 results showing a return to profitability at the operating level and a narrower bottom-line loss. Net operating income was $1.6 million, an improvement of $3.3 million from 2024, driven by stronger gross margins from higher volumes, manufacturing efficiencies and pricing.
Full-year product sales rose 4.3% to $27.6 million, while gross profit increased to $11.4 million from $7.9 million. Despite several non‑recurring charges, including a $2.7 million Re‑Tain® write‑down and $651,000 of colostrum inventory write‑downs, net loss improved to $1.0 million from $2.2 million. EBITDA nearly doubled to $2.2 million. Year-end cash was $3.8 million with positive operating cash flow of $2.5 million, and management highlighted a strategic focus on its First Defense® franchise.
ImmuCell Corporation reported that two directors, Steven A. Rosgen and Bryan K. Gathagan, have each notified the company that they prefer not to run for re-election at the 2026 Annual Meeting of Shareholders. Both directors are described as supportive of the company’s new strategic direction and management team, but cited time constraints from full-time leadership roles at their own companies. The Board’s Nominating Committee has been reviewing possible changes to Board composition and will now incorporate these planned retirements into its ongoing work.
ImmuCell Corporation updated compensation arrangements for key executives. Effective January 27, 2026, new employment agreements set annual base salaries of $315,000 for CFO Timothy C. Fiori and $300,000 for Senior VP of Sales and Marketing Bobbi Jo Brockmann. Beginning with the fiscal year ending December 31, 2026, each can earn a formula-based annual cash bonus targeting 50% of base salary, rising to 60% if preset financial and strategic targets are exceeded by at least 20%. The Compensation and Stock Option Committee also granted Fiori an option for 120,000 shares and Brockmann an option for 100,000 shares under the 2025 Stock Option and Incentive Plan, vesting in three equal annual installments from January 2027 at an exercise price of $6.26 per share, with potential accelerated vesting upon a change of control or certain terminations. CEO Olivier te Boekhorst received a performance-based option for 110,000 shares at $6.26 per share, vesting only if net operating income for four consecutive quarters reaches at least 300% of audited 2025 net operating income.
ImmuCell Corporation filed a Form 4 for Chief Financial Officer and director Timothy C. Fiori reporting a new stock option grant. On January 27, 2026, he received 120,000 stock options with an exercise price of $6.265 per share, held directly.
The option is intended to qualify as an incentive stock option to the maximum extent allowed under the Internal Revenue Code, with the remainder as a nonqualified option. It vests in three equal tranches of 40,000 options on each of the first, second, and third anniversaries of the grant date.
ImmuCell Corporation filed a Form 4 showing an option grant to executive and director Bobbi Jo Brockmann. On January 27, 2026, she received stock options to purchase 100,000 shares of common stock at an exercise price of $6.265 per share, expiring on January 27, 2036.
The options were granted in connection with her role as Vice President of Sales and Marketing. They vest over three years: 33,333 shares become exercisable on each of January 27, 2027 and January 27, 2028, and 33,334 shares become exercisable on January 27, 2029. Following this grant, she beneficially owns 100,000 derivative securities directly.